Hjem › Sklerodermi › Californien
Sklerodermi kliniske forsøg i Californien
13 studier for Sklerodermi søger deltagere på steder i Californien.
Byer i Californien
Officiel studietekst (engelsk)
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- University of California Los Angeles, Los Angeles
- Paradigm Clinical Research - San Diego, San Diego
- Stanford University School of Medicine, Stanford
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07497087A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
- UCLA Ronald Reagan University of California Los Angeles Medical Center, Los Angeles
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT06655155Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- University of California Davis Comprehensive Cancer Center, Sacramento
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT03816345A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Loma Linda University Medical Center, Loma Linda
RekruttererFase 1
Alder 18 til 74 · Alle køn · Opdateret 10. sep. 2026 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- og 1 flere
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT05878717FT839 in Autoimmune Diseases
- Providence Medical Foundation, Fullerton
RekruttererFase 1/2
Alder 18 til 70 · Alle køn · Opdateret 2. sep. 2026 · NCT07800871A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- UC San Diego Health, La Jolla
- Stanford University Medical Center, Redwood City
RekruttererFase 1
Alder 18 til 70 · Alle køn · Opdateret 28. aug. 2026 · NCT06925542Platform Clinical Study for Conquering Scleroderma
- Keck School of Medicine at USC Medical Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Stanford University Medical Center, Palo Alto
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 18. aug. 2026 · NCT06195072A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Orange
RekruttererFase 1/2
Alder 18 til 75 · Alle køn · Opdateret 7. aug. 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Chula Vista, Chula Vista
- Artiva Investigational Site Covina, Covina
- Artiva Investigational Site Los Alamitos, Los Alamitos
- og 3 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 31. jul. 2026 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Stanford
RekruttererFase 1
Alder 18 til 75 · Alle køn · Opdateret 28. jul. 2026 · NCT07295847A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Wallace Rheumatic Center, Beverly Hills
- Providence Medical Foundation, Fullerton
- University of California Irvine, Irvine
- og 2 flere
RekruttererFase 1
Alder 12 til 70 · Alle køn · Opdateret 22. maj 2026 · NCT06308978Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Los Angeles
- aTyr Investigative Site, San Diego
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 7. maj 2025 · NCT05892614Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.